US Patent 8,546,428: Bedaquiline Fumarate Formulation Claims, Expiry, and Patent Landscape
US Patent 8,546,428 protects specific solid oral formulations of bedaquiline fumarate, particularly tablets containing a polyethylene glycol sorbitan fatty acid ester such as polysorbate 20. The patent also claims wet-granulation processes, manufacture of the fumarate salt, and treatment of tuberculosis using the claimed composition.
The patent is formulation-focused. It does not broadly cover every bedaquiline product, every bedaquiline salt, or every treatment method using bedaquiline. Its principal commercial relevance is to Sirturo tablets and generic products that replicate the protected excipient system or manufacturing process.
What drug does US Patent 8,546,428 protect?
The active ingredient named in the claims is the fumarate salt of bedaquiline, formerly identified by its full stereochemical chemical name:
"(alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol fumarate."
Bedaquiline is a diarylquinoline antimycobacterial agent marketed by Johnson & Johnson through Janssen as Sirturo. The FDA approved Sirturo tablets in 2012 through the accelerated-approval pathway for multidrug-resistant tuberculosis in combination with other agents [1].
What is the commercial product?
| Item |
Information |
| Brand |
Sirturo |
| Active ingredient |
Bedaquiline fumarate |
| Dosage form |
Oral tablet |
| Commercial strength |
100 mg bedaquiline base equivalent |
| FDA application |
NDA 204384 |
| Initial FDA approval |
December 28, 2012 |
| Therapeutic area |
Tuberculosis, including multidrug-resistant tuberculosis |
| Patent subject |
Formulation, manufacturing process, salt preparation, and treatment method |
The 100 mg strength is directly reflected in claim 6, which specifies 120.89 mg of bedaquiline fumarate corresponding to 100 mg of bedaquiline base.
What are the independent claims in US Patent 8,546,428?
The patent has four principal claim groups:
- A solid pharmaceutical composition containing bedaquiline fumarate and a polyethylene glycol sorbitan fatty acid ester.
- A manufacturing process for the tablet composition.
- A process for preparing bedaquiline fumarate by reacting the free base with fumaric acid.
- A treatment method for mycobacterial infection, including tuberculosis.
Claim structure
| Claim |
Subject matter |
Practical scope |
| 1 |
Solid composition with bedaquiline fumarate and PEG sorbitan fatty acid ester |
Core composition claim |
| 2 |
Composition suitable for oral administration |
Narrows claim 1 |
| 3 |
Quantitative composition ranges |
Narrows claim 1 by weight percentages |
| 4 |
Tablet dosage form |
Narrows claim 1 |
| 5 |
Tablet-core excipient ranges |
Narrows claim 4 |
| 6 |
Specific 100 mg tablet formula |
Narrowest formulation claim |
| 7 |
Film-coated tablet |
Narrows claim 4 |
| 8 |
Wet-granulation process using binder and wetting-agent solution |
Manufacturing-process claim |
| 9 |
Alternative granulation process |
Manufacturing-process claim |
| 10 |
Preparation of fumarate salt from free base and fumaric acid |
Salt-manufacturing claim |
| 11 |
Treatment of mycobacterial infection using claim 1 composition |
Method-of-treatment claim |
| 12 |
Treatment of tuberculosis |
Narrower method claim |
What does claim 1 require?
Claim 1 requires all of the following:
- A solid pharmaceutical composition.
- A pharmaceutically acceptable carrier.
- A therapeutically effective amount of bedaquiline fumarate.
- A wetting agent.
- The wetting agent must be a polyethylene glycol sorbitan fatty acid ester.
The final limitation is central. Typical compounds in this class include:
- Polysorbate 20.
- Polysorbate 40.
- Polysorbate 60.
- Polysorbate 65.
- Polysorbate 80.
- Other polyethylene glycol sorbitan fatty acid esters, depending on the precise chemical structure and claim construction.
A solid formulation containing bedaquiline fumarate but using a different wetting agent may avoid literal infringement of claim 1. A formulation without any wetting agent would also fall outside the literal wording of claim 1, subject to possible doctrine-of-equivalents arguments.
The claim does not require a tablet. A capsule, powder, granule, sachet, or other solid dosage form could potentially fall within claim 1 if it contains the required active ingredient, carrier, and wetting agent.
What formulation is protected by claim 6?
Claim 6 is directed to a specific tablet-core composition:
| Component |
Amount per tablet |
| Bedaquiline fumarate |
120.89 mg |
| Lactose monohydrate, 200 mesh |
152.91 mg |
| Maize starch |
66.0 mg |
| Hypromellose 2910, 15 mPa·s |
8.0 mg |
| Polysorbate 20 |
1.0 mg |
| Microcrystalline cellulose |
82.2 mg |
| Croscarmellose sodium |
23.0 mg |
| Colloidal silicon dioxide |
1.4 mg |
| Magnesium stearate |
4.6 mg |
The total uncoated core weight is approximately 470 mg. The claim identifies polysorbate 20 as the wetting agent and uses a conventional direct-compression or wet-granulation excipient system involving lactose, starch, hypromellose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
Claim 6 is commercially important but relatively narrow. A generic manufacturer could seek design-around protection by changing one or more of the following:
- Wetting agent.
- Diluent.
- Binder.
- Disintegrant.
- Glidant.
- Lubricant.
- Excipient concentration.
- Granulation sequence.
- Tablet-core composition.
A design-around must be evaluated against both the literal language of the claim and potential infringement under the doctrine of equivalents.
What percentage ranges are covered?
Claim 3 requires the following composition ranges:
| Component |
Claimed range |
| Active ingredient |
5% to 50% |
| PEG sorbitan fatty acid ester |
0.01% to 5% |
| Diluent |
40% to 92% |
| Glidant |
0.1% to 5% |
Claim 5 adds ranges for a tablet core:
| Component |
Claimed range |
| Active ingredient |
5% to 50% |
| Wetting agent |
0.01% to 5% |
| Diluent |
40% to 92% |
| Polymer |
0% to 10% |
| Disintegrant |
2% to 10% |
| Glidant |
0.1% to 5% |
| Lubricant |
0.1% to 1.5% |
The use of "0%" for the polymer limitation means that a polymer is optional under claim 5. Hypromellose is present in claim 6, but claim 5 does not require it.
What manufacturing processes are protected?
Claims 8 and 9 protect wet-granulation routes for producing the tablet.
Claim 8 process
The claimed sequence is:
- Dry blend bedaquiline fumarate with part of the diluent.
- Dissolve the binder and wetting agent in a solvent.
- Spray the solution onto the dry blend.
- Dry, sieve, and optionally mix the wet granulate.
- Add the remaining diluent, disintegrant, and optional glidant.
- Add lubricant, if used.
- Compress the mixture into tablets.
- Optionally apply a film coating.
Claim 9 process
Claim 9 is broader in certain respects because the granulation solution may optionally contain the binder and wetting agent. It also permits the binder and wetting agent to be added later during the post-granulation mixing stage.
The process claims create an infringement risk even where a finished tablet does not precisely match claim 6. A generic manufacturer using the same sequence, bedaquiline fumarate, and covered excipients could face process-claim exposure.
The process claims are likely easier to design around than the composition claims. Alternative approaches may include:
- Dry granulation.
- Roller compaction.
- Direct compression.
- Separate addition of the wetting agent.
- Use of a noncovered surfactant.
- Use of a solvent-free granulation process.
What does claim 10 protect?
Claim 10 covers preparation of the fumarate salt by reacting bedaquiline free base with fumaric acid in a suitable solvent.
The claim is narrower than a claim covering all processes for manufacturing bedaquiline fumarate. It requires:
- The corresponding bedaquiline free base.
- Fumaric acid.
- A suitable solvent.
- A reaction that produces the claimed fumarate product.
A process using a preformed fumarate salt, a different acid-addition route, or a different salt-forming reagent may avoid literal infringement. The scope would depend on the construction of "reacting" and "suitable solvent," as well as any limitations imported from the specification.
What treatment methods are covered?
Claims 11 and 12 cover administering the claimed composition to a patient with a mycobacterial infection.
Claim 12 is limited to tuberculosis. The method claims require use of the composition of claim 1, meaning the treatment must involve a solid composition containing bedaquiline fumarate and a PEG sorbitan fatty acid ester.
These claims do not necessarily cover:
- Intravenous bedaquiline.
- A different bedaquiline salt.
- A formulation without the specified wetting agent.
- Treatment using bedaquiline free base.
- Treatment of a nonmycobacterial infection.
The claims also do not expressly recite the full Sirturo dosing schedule. Infringement analysis would focus on the composition administered and the factual circumstances of manufacture, sale, or use.
When does US Patent 8,546,428 lose exclusivity?
US Patent 8,546,428 was granted on October 1, 2013. The patent derives from an earlier priority filing, and its projected statutory expiration is in the late 2027 period based on the patent-family priority structure. The applicable expiration date should be determined from the USPTO patent-term calculation and any listed FDA patent data because patent-term adjustment can alter the ordinary 20-year calculation [2, 3].
| Exclusivity category |
Relevance to Sirturo |
| New chemical entity exclusivity |
Expired in 2017 |
| Orphan-drug exclusivity |
Not the principal barrier for current U.S. entry analysis |
| Original compound patent |
Earlier bedaquiline protection has expired or reached the end of its term |
| US 8,546,428 |
Later formulation and process barrier |
| Additional formulation or crystalline-form patents |
Must be assessed separately in the Orange Book and USPTO records |
The practical generic-entry date depends on the complete Orange Book listing, any unexpired related patents, Paragraph IV litigation, pediatric exclusivity, settlements, and regulatory approval timing.
What is the Orange Book status of Sirturo?
Sirturo is an FDA-approved small-molecule drug, so its relevant patent listings are in the FDA Orange Book rather than a biologics patent framework.
The Orange Book analysis should distinguish between:
- Patents covering the active chemical compound.
- Patents covering bedaquiline salts.
- Formulation patents.
- Method-of-use patents.
- Manufacturing-process patents, which may not receive the same Orange Book listing treatment as drug-product or method-of-use patents.
US 8,546,428 is principally a formulation and manufacturing patent. Its commercial importance depends on whether it is listed against the relevant Sirturo dosage form and whether a generic applicant must certify to it under an abbreviated new drug application.
What Paragraph IV challenges could target this patent?
A generic applicant could use a Paragraph IV certification asserting that the patent is:
- Invalid.
- Unenforceable.
- Not infringed.
- Not relevant to the proposed product.
The strongest potential noninfringement positions would involve:
- Use of a different wetting agent.
- Use of bedaquiline free base or a different salt.
- A non-solid dosage form.
- Direct compression instead of the claimed granulation process.
- Excipients outside the stated ranges.
- A formulation that does not contain a PEG sorbitan fatty acid ester.
Potential validity arguments could include:
- Anticipation by an earlier formulation disclosure.
- Obviousness based on known bedaquiline formulations and conventional tablet excipients.
- Lack of written description for the full genus of PEG sorbitan fatty acid esters.
- Enablement concerns across the full scope of the wetting-agent class.
- Indefiniteness involving "therapeutically effective amount," "suitable solvent," or "optionally" drafted limitations.
The patent's strongest claim is likely claim 6 when a competing product closely replicates the listed formula. Claims 1 and 3 have greater commercial breadth but may present more substantial prior-art and written-description issues.
How strong is the patent estate?
| Estate segment |
Strength assessment |
| Bedquiline fumarate tablet composition |
Moderate to strong if the generic uses polysorbate 20 or a related covered surfactant |
| Exact Sirturo-like formulation |
Stronger on literal infringement, narrower commercially |
| Wet-granulation process |
Moderate, depending on access to the generic manufacturing process |
| Fumarate-salt preparation |
Moderate, with design-around potential |
| Tuberculosis treatment method |
Moderate, but dependent on the composition limitation |
| Broad bedaquiline molecule protection |
Separate earlier patent estate; not the core of US 8,546,428 |
| Biosimilar protection |
Not applicable because bedaquiline is a small molecule |
The estate is more vulnerable to formulation substitution than to simple copying of the active ingredient. A generic manufacturer can use the same bedaquiline fumarate while pursuing a different excipient system and manufacturing route.
What licensing and access arrangements affect bedaquiline?
Janssen entered into access arrangements involving bedaquiline for multidrug-resistant tuberculosis. The Global Drug Facility and public-health organizations have negotiated access and supply mechanisms, while the United States and other jurisdictions have used procurement and licensing arrangements to expand availability in high-burden countries [4, 5].
Those arrangements do not automatically eliminate U.S. patent rights. Their effect depends on:
- Territory.
- Product source.
- Authorized manufacturer.
- Field of use.
- Volume restrictions.
- Government procurement terms.
- Patent rights in the relevant jurisdiction.
Bedaquiline patent coverage is geographically fragmented. A U.S. patent cannot block manufacture or sale in countries where corresponding patents have expired, were not granted, or were challenged successfully.
What generic launch risks exist?
A generic applicant faces four primary risks:
- Product-formulation risk if the proposed tablet uses a covered polysorbate-based system.
- Process risk if the applicant uses the claimed wet-granulation sequence.
- Regulatory risk from Orange Book certifications and a possible 30-month stay.
- Commercial risk from limited market size, public-health procurement, and pricing pressure.
A design-around product using a different surfactant and direct compression could materially reduce infringement exposure. The resulting formulation would still require comparative bioavailability, stability, dissolution, and manufacturing validation.
Key Takeaways
- US Patent 8,546,428 is a bedaquiline fumarate formulation and manufacturing patent, not a broad compound patent.
- Claim 1 requires a solid composition containing bedaquiline fumarate and a PEG sorbitan fatty acid ester.
- Claim 6 closely tracks the 100 mg Sirturo tablet core, including polysorbate 20.
- Claims 8 and 9 cover wet-granulation manufacturing routes.
- Claim 10 covers preparation of bedaquiline fumarate from the free base and fumaric acid.
- Claims 11 and 12 cover treatment of mycobacterial infection and tuberculosis using the claimed composition.
- The patent's projected term reaches the late 2027 period, subject to the official patent-term calculation.
- The principal generic design-around options are changing the wetting agent, changing the salt, using direct compression, or adopting a different granulation process.
- Bedaquiline is a small molecule, so biosimilar analysis does not apply.
- The commercial patent risk depends on the full Sirturo Orange Book listing and any later formulation or method-of-use patents.
FAQs
Does US Patent 8,546,428 cover all bedaquiline tablets?
No. It covers tablets and other solid compositions that meet the claim limitations, including bedaquiline fumarate and a PEG sorbitan fatty acid ester. A bedaquiline tablet using a different salt or wetting agent may fall outside the literal claims.
Is polysorbate 20 required in every claim?
No. Claim 6 specifically identifies polysorbate 20. Claim 1 covers the broader class of polyethylene glycol sorbitan fatty acid esters. Other claims use functional and quantitative limitations rather than requiring polysorbate 20 by name.
Can a generic manufacturer use bedaquiline fumarate without infringing this patent?
Potentially. The manufacturer would need to avoid the covered composition limitations and the claimed process steps. Use of bedaquiline fumarate alone does not establish infringement of claim 1.
Does the patent cover bedaquiline intravenous formulations?
The claims are directed to solid pharmaceutical compositions and tablet manufacturing. They do not expressly cover an intravenous liquid formulation that lacks the claimed solid dosage-form elements.
Is a bedaquiline generic subject to biosimilar approval requirements?
No. Bedaquiline is a chemically synthesized small molecule. A generic product would generally proceed under the abbreviated new drug application pathway rather than the biologics license application and biosimilar pathways.
References
- U.S. Food and Drug Administration. (2012). Sirturo (bedaquiline fumarate) prescribing information.
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,546,428: Pharmaceutical compositions comprising bedaquiline fumarate.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Global Drug Facility. (2023). Bedaquiline procurement and access information.
- World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment.